Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01839981 · ClinicalTrials.gov registry record · Phase 1
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01839981 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 10 participants.
The verdict
NCT01839981, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer. Drugs used in chemotherapy, such as 6,8-bis(benzylthio)octanoic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- DRUG 6,8-bis(benzylthio)octanoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01839981
The ClinicalTrials.gov registry entry for NCT01839981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 6,8-bis(benzylthio)octanoic acid is the first listed.
NCT01839981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01839981 about?
NCT01839981 is a clinical study titled "CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer. Drugs used in chemotherapy, such as 6,8-bis(benzylthio)octanoic acid, work in different ways to stop the growth of tumor cells, either by killing the cells o...
What is the current status of trial NCT01839981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-07. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01839981?
The interventions under investigation include: 6,8-bis(benzylthio)octanoic acid (DRUG).
Who is sponsoring clinical trial NCT01839981?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.